MedTrace Logo

Phase 1 Single Dose Escalation Study of CTB-001

NCT01647893 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2012-07-24

No results posted yet for this study

Summary

A Phase 1 Clinical Study, Randomized, Double-blind, Placebo-controlled, Single-dose, Dose Escalation Study of the Safety and Pharmacokinetic/Pharmacodynamic Profiles of CTB-001 Intravenously Administered in Healthy Male Subjects

Conditions

  • Healthy

Interventions

DRUG

CTB-001

IV bolus or IV infusion

Sponsors & Collaborators

  • HLB Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Kyun-Seop Bae, M.D., Ph.D. · Asan Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2012-11-30
Completion
2012-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01647893 on ClinicalTrials.gov